Modern Phenotypic Drug Discovery: From Chemical Biology to Therapeutics

摘要 请求支持Keystone研讨会会议，题为现代表型药物发现：从 化学生物学治疗学，由布里奇特瓦格纳博士，尼尔卡拉格，杰里米詹金斯和 劳拉·基斯林。会议将于2022年5月22日至25日在科罗拉多州丹佛市举行。 表型药物发现（Phenotypic Drug Discovery，PDD）作为药物发现和化学生物学研究的一种方法，已逐渐建立起来 学术界和工业界的动力和兴奋。新技术平台的融合 (e.g.,诱导多能干细胞，CRISPR-Cas9基因编辑，3D生物学，先进成像）与其他 化学信息学、机器学习和人工智能等学科已经带来了令人兴奋的 PDD的复兴本次会议将汇集研究人员进行或感兴趣的表型 来自学术界和工业界的药物发现。尽管PDD的现代进展跨越了学术和学术两个层面， 和工业部门，很少有非商业药物发现为重点的会议， Keystone Symposia计划是这个主题的首要论坛。本次会议旨在 分享PDD新技术、生物模型和人类疾病领域的信息和最佳实践， 并促进学术界和工业界的合作讨论。此外，本次会议 该计划将解决该领域的几个关键障碍：如何提高生理相关性， 表型模型和识别表型目标并理解化合物的作用机制 （农业部）。预计与会者将离开一个新的赞赏表型战略， 化学生物学领域的广泛领域，通过扩大我们的集体努力， 推动改进的分析模型和尖端MoA技术的界限。

ABSTRACT Support is requested for a Keystone Symposia conference entitled Modern Phenotypic Drug Discovery: From Chemical Biology to Therapeutics, organized by Drs. Bridget Wagner, Neil Carragher, Jeremy Jenkins and Laura Kiessling. The conference will be held in Denver, Colorado from May 22-25, 2022. Phenotypic Drug Discovery (PDD) as an approach to drug discovery and chemical biology has been building momentum and excitement in both academia and industry. The convergence of new technology platforms (e.g., induced pluripotent stem cells, CRISPR-Cas9 gene editing, 3D biology, advanced imaging) with other disciplines such as cheminformatics, machine learning, and artificial intelligence have led to an exciting renaissance of PDD. This conference will bring together researchers performing or interested in phenotypic drug discovery from across academia and industry. Although modern advances in PDD span both academic and industry sectors, there are few non-commercial drug discovery-focused meetings available for the community, and the Keystone Symposia program is a premiere forum for this topic. This conference aims to share information and best practices in new PDD technologies, biological models, and human disease areas, as well as foster collaborative discussions across academia and industry. Additionally, this conference program will address several critical barriers in the field: how to improve the physiological relevance of phenotypic models and identifying a phenotypic target and understanding a compound’s mechanism of action (MoA). It is anticipated that attendees will leave with a renewed appreciation for phenotypic strategies in a wide variety of areas in chemical biology, and that the field will be advanced by expanding our collective efforts to push the boundaries of improved assay models and cutting-edge MoA technologies.